BiotechTube

Olaparib 300mg tablets

Phase 3Active
1 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Newly Diagnosed

Conditions

Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation, Complete Response, Partial Response, First Line Platinum Chemotherapy

Trial Timeline

Aug 26, 2013 → Aug 29, 2028

NCT ID
NCT01844986

About Olaparib 300mg tablets

Olaparib 300mg tablets is a phase 3 stage product being developed by AstraZeneca for Newly Diagnosed. The current trial status is active. This product is registered under clinical trial identifier NCT01844986. Target conditions include Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV.

What happened to similar drugs?

0 of 4 similar drugs in Newly Diagnosed were approved

Approved (0) Terminated (1) Active (3)
🔄Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimenAmgenPhase 3
🔄Elranatamab + Lenalidomide (Revlimid®) + Daratumumab SC (Darzalex) + Bortezomib (Velcade®) + DexamethasonePfizerPhase 3
❌Lenalidomide + Dexamethasone + ElotuzumabBristol Myers SquibbPhase 3
🔄Bortezomib + Isatuximab + Iberdomide + Lenalidomide + DexamethasoneBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical
17
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03534453Phase 3Completed
NCT01844986Phase 3Active

Competing Products

18 competing products in Newly Diagnosed

See all competitors
ProductCompanyStageHype Score
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
32
Gliadel Wafer + TemozolomideEisaiPhase 2
31
PembrolizumabMerckPhase 2
39
Drug (including placebo)MerckPhase 1
21
CilengitideMerckPhase 2
31
[177Lu]Lu-NeoB + [68Ga]Ga-NeoBNovartisPhase 1
33
BKM120 + Trastuzumab + Paclitaxel + BKM120 PlaceboNovartisPhase 2
35
Tecentriq 1200 MG in 20 ML Injection + H3K27M peptide vaccineRochePhase 1
33
ZenapaxRochePhase 2
35
Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimenAmgenPhase 3
47
Elranatamab + Lenalidomide (Revlimid®) + Daratumumab SC (Darzalex) + Bortezomib (Velcade®) + DexamethasonePfizerPhase 3
47
Elranatamab + Daratumumab + LenalidomidePfizerPhase 2
42
Lenalidomide + Dexamethasone + ElotuzumabBristol Myers SquibbPhase 3
32
Bortezomib + Isatuximab + Iberdomide + Lenalidomide + DexamethasoneBristol Myers SquibbPhase 3
47
Isatuximab-Irfc 20 MG/ML [Sarclisa] + Lenalidomide + Dexamethasone OralSanofiPhase 2
39
MebendazoleBrain BiotechPhase 1
19
Balstilimab + Botensilimab + Liposomal DoxorubicinAgenusPhase 2
32
HLA-A2 restricted glioma antigen peptides vaccine + Poly-ICLCBrain BiotechPhase 1
19